2025 Early Career Investigator Award
Supports early-career researchers advancing innovative basic, translational, or clinical studies to improve understanding and treatment of metastatic (stage IV) breast cancer.
Funder: METAvivor
Due Dates (Anticipated): March 2026 (Letter of Intent) | August 2026 (Invited full application & internal submission) | December 2026 (Funding organization's deadline)
Funding Amounts: Up to $200,000 total over two years; includes direct costs (with up to $3,000 for travel) and up to 5% indirect costs.
Summary: Supports innovative research by early-career investigators to advance treatment and understanding of metastatic breast cancer.
Description
This award supports promising early-career investigators conducting novel, high-quality research in metastatic (stage IV) breast cancer. The program aims to fund basic, translational, and clinical research that addresses critical challenges or barriers in the field, with an emphasis on projects likely to benefit patients living with metastatic disease. Preference is given to studies focused on established metastases, mechanistic insights, or pre-clinical animal research that could lead to improved clinical outcomes or lay the groundwork for future treatment advances. Projects focused solely on prevention or diagnosis (except for novel diagnostic tools monitoring metastatic progression) are not eligible. The award is designed to help early-stage researchers establish a foundation for future work in metastatic breast cancer.
